Moving forward in partnership with the community
Imara’s phase 1 clinical trial in healthy volunteers showed IMR-687 to be safe and well tolerated. Imara has initiated a phase 2a clinical trial with IMR-687 in adult patients with sickle cell disease. Please visit clinicaltrials.gov for more information. Be sure to check back here for progress updates.